Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04583423 · ClinicalTrials.gov registry record · Phase 2
A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Terminated
- Registry status
- Phase 2
- Development phase
- 183
- Enrollment target
NCT04583423 is a Phase 2 study that was terminated before completion, run by Merck Sharp & Dohme. The registered enrollment target is 183 participants.
The verdict
NCT04583423, a Phase 2 study, was terminated before completion, sponsored by Merck Sharp & Dohme.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 183 participants
- Enrollment target
Study Summary
This study will evaluate the effect of each dose of MK-3655 versus placebo on the percentage of individuals with NASH resolution without worsening of fibrosis after 52 weeks. The primary hypothesis of the study is that at least 1 dose of MK-3655 is superior to placebo with respect to the percentage of individuals with NASH resolution without worsening of fibrosis after 52 weeks.
Interventions
- DRUG Placebo
- DRUG MK-3655
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2020-11-11 |
| Est. Completion | 2023-04-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04583423
The ClinicalTrials.gov registry entry for NCT04583423 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04583423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04583423 about?
NCT04583423 is a clinical study titled "A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)". This study will evaluate the effect of each dose of MK-3655 versus placebo on the percentage of individuals with NASH resolution without worsening of fibrosis after 52 weeks. The primary hypothesis of the study is that at least 1 dose of MK-3655 is superior to placebo with respect to the percentage ...
What is the current status of trial NCT04583423?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 183 participants. The study started on 2020-11-11. Estimated completion is 2023-04-13.
What interventions are being tested in trial NCT04583423?
The interventions under investigation include: Placebo (DRUG), MK-3655 (DRUG).
Who is sponsoring clinical trial NCT04583423?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.